Thus, the unexpected discovery that VIRMA-overexpressing cancer cells are more sensitive to UPR presents a previously undescribed “Achilles Heel” of breast cancer subtypes that may be useful for the development of precision intervention. Here, VIRMA is linked to breast cancer.